Assertio Therapeutics Inc (ASRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has a cash flow conversion efficiency ratio of 0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.56 Million) by net assets ($75.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Assertio Therapeutics Inc (ASRT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Assertio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Assertio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assertio Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Horizon Gold Ltd
AU:HRN
|
-0.016x |
|
Cho Kwang Leat
KO:004700
|
0.003x |
|
Amulaire Thermal Technology
TW:2241
|
0.007x |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
0.238x |
|
Leclanche SA
SW:LECN
|
0.518x |
|
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
|
0.070x |
|
Tofu Restaurant Co Ltd
TWO:2752
|
0.148x |
|
USBC, Inc.
NYSE MKT:USBC
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Assertio Therapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see ASRT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.95 Million | $-28.18 Million | -0.300x | -237.53% |
| 2024-12-31 | $121.08 Million | $26.41 Million | 0.218x | -39.32% |
| 2023-12-31 | $138.00 Million | $49.60 Million | 0.359x | +3.23% |
| 2022-12-31 | $225.72 Million | $78.60 Million | 0.348x | +545.68% |
| 2021-12-31 | $102.41 Million | $5.52 Million | 0.054x | +104.57% |
| 2020-12-31 | $55.51 Million | $-65.57 Million | -1.181x | -175.67% |
| 2019-12-31 | $57.96 Million | $90.47 Million | 1.561x | +374.44% |
| 2018-12-31 | $220.34 Million | $72.50 Million | 0.329x | -10.28% |
| 2017-12-31 | $169.51 Million | $62.17 Million | 0.367x | +40.42% |
| 2016-12-31 | $250.79 Million | $65.50 Million | 0.261x | -42.81% |
| 2015-12-31 | $315.06 Million | $143.89 Million | 0.457x | +397.67% |
| 2014-12-31 | $364.45 Million | $-55.92 Million | -0.153x | -316.15% |
| 2013-12-31 | $137.42 Million | $9.75 Million | 0.071x | +119.23% |
| 2012-12-31 | $83.94 Million | $-30.98 Million | -0.369x | -167.82% |
| 2011-12-31 | $105.92 Million | $57.65 Million | 0.544x | +628.20% |
| 2010-12-31 | $23.11 Million | $-2.38 Million | -0.103x | -188.17% |
| 2009-12-31 | $15.73 Million | $1.84 Million | 0.117x | +15.63% |
| 2008-12-31 | $33.15 Million | $3.35 Million | 0.101x | -68.62% |
| 2007-12-31 | $45.52 Million | $14.66 Million | 0.322x | -68.27% |
| 2006-12-31 | $-27.29 Million | $-27.70 Million | 1.015x | -76.18% |
| 2005-12-31 | $6.76 Million | $28.82 Million | 4.262x | +253.93% |
| 2004-12-31 | $8.40 Million | $-23.27 Million | -2.769x | -188.82% |
| 2003-12-31 | $34.58 Million | $-33.15 Million | -0.959x | -238.57% |
| 2002-12-31 | $-6.41 Million | $-4.44 Million | 0.692x | -91.76% |
| 2001-12-31 | $-1.48 Million | $-12.40 Million | 8.393x | +678.64% |
| 2000-12-31 | $4.59 Million | $-6.65 Million | -1.451x | -238.96% |
| 1999-12-31 | $9.22 Million | $-3.94 Million | -0.428x | -57.48% |
| 1998-12-31 | $9.20 Million | $-2.50 Million | -0.272x | -1.28% |
| 1997-12-31 | $4.10 Million | $-1.10 Million | -0.268x | -126.83% |
| 1996-12-31 | $-400.00K | $-400.00K | 1.000x | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more